A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Phase of Trial: Phase IV
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 26 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Jun 2021.
- 26 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 May 2021.